Breaking News

Daiichi Sankyo in Drug Discovery Collaboration

Enters cancer research partnership with Max Planck Innovation and Lead Discovery Center

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Daiichi Sankyo, Max Planck Innovation GmbH and the Lead Discovery Center GmbH have signed an agreement providing Daiichi Sankyo with the option to receive the exclusive rights to a new lead compound for the treatment of cancer to be discovered and developed at the Lead Discovery Center. This new partnership builds on biology insights in the field of transcriptional regulation from the work of Prof. Matthias Geyer at the Max Planck Institute of Molecular Physiology in Dortmund and the Research...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters